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 INTRODUCTION 
 Individual informed consent is internationally recognized 
as an ethical requirement for research involving human par-
ticipants. 1 Valid informed consent has four components: 1) 
the person giving consent must be competent, 2) relevant 
information must be disclosed, 3) the person must under-
stand the information, and 4) the consent must be voluntarily 
given. Exactly how much must be understood is controver-
sial. 2 However, most commentators consider that participants 
should at least understand the potential risks and benefits of 
the research, the ways in which participation will or will not 
differ from clinical care, and what will happen if participants 
want to withdraw. 1, 3, 4 
 An increasing number of trials are now being conducted 
in developing countries. 5 Some reviewers are concerned that 
the participants in these trials are poor, often uneducated, 
and unfamiliar with the scientific basis of modern medicine. 6, 7 
Consequently, these research participants are thought less 
likely to understand the research and thus less likely to pro-
vide valid informed consent compared with participants from 
developed countries. 
 A number of studies have assessed trial participants’ under-
standing of research and their perceptions of voluntariness. 
In both developed and developing countries, studies show 
wide variation in understanding on most required elements. 8 
Scientific concepts like randomization are particularly difficult 
for participants from either location to understand. However, 
there is not clear evidence of substantial differences in under-
standing between participants from developed compared with 
developing countries, 9 although there are some indications 
that developing country participants are more likely to feel 
pressure to enroll. 10– 12 These conclusions are tentative, because 
these studies look at participants in widely varying clinical 
trials. For instance, many of the studies of understanding in 
developed countries were Phase I oncology studies, which are 
not currently conducted in developing countries. Furthermore, 
the instruments used to assess the quality of understanding of 
research participants vary widely between studies, and few 
instruments have been validated. 
 This work reports consent data on participants in early phase 
trials of malaria vaccine candidates in the United States and in 
two villages in Mali, West Africa. As part of the informed con-
sent process, questionnaires were administered to all partici-
pants or parent/guardians of pediatric participants who were 
screened for eligibility. The questionnaires were intended to 
confirm that potential participants understood the essential 
elements of the research before participation, and were not 
prospectively intended to collect data. However, to our knowl-
edge, these data are the first to allow a direct comparison of 
the understanding of consent of similar clinical trials in the 
developed and developing world. 
 METHODS 
 Sites and participants.  The Malaria Vaccine Development 
Branch, National Institute of Allergy and Infectious Diseases 
(MVDB/NIAID/NIH) develops recombinant protein malaria 
vaccines intended to reduce the severity and frequency of 
falciparum malaria. Two Phase 1 clinical trials were conducted 
in malaria naive adults at the Johns Hopkins University Center 
for Immunization Research (JHU/CIR) in Washington DC 
and one Phase 1 clinical trial was conducted in semi-immune 
adults in Donéguébougou, Mali. 13– 15 A Phase 1,2 study was 
also conducted in 2–3 year old children in Donéguébougou 
and Bancoumana, Mali, with most of the participants recruited 
in Bancoumana, the larger village. 16, 17 Three different vaccines 
were evaluated (AMA1-C1/Alhydrogel in Malian children, 
AMA1-C1/Alhydrogel+/−CPG 7909 in United States adults 
and Malian adults, and MSP1 42 -C1/Alhydrogel+/−CPG 7909 in 
United States adults); all were recombinant protein vaccines 
targeting blood stage malaria. All trials were conducted under 
protocols reviewed by the Institutional Review Board of the 
 Comparing the Understanding of Subjects Receiving a Candidate 
Malaria Vaccine in the United States and Mali 
 Ruth D.  Ellis ,  Issaka  Sagara ,  Anna  Durbin ,  Alassane  Dicko ,  Donna  Shaffer ,  Louis  Miller ,  Mahamadoun H.  Assadou , 
 Mamady  Kone ,  Beh  Kamate ,  Ousmane  Guindo ,  Michael P.  Fay ,  Dapa A.  Diallo ,  Ogobara K.  Doumbo ,  Ezekiel J.  Emanuel , 
and  Joseph  Millum * 
 Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland; 
Malaria Research and Training Center, Faculty of Medicine Pharmacy and Dentistry, University of Bamako, Bamako, Mali; Johns Hopkins Center 
for Immunization Research, Washington, DC; Biostatistics Research Branch, NIAID/NIH; Clinical Center Department of Bioethics, NIH; 
Clinical Center Department of Bioethics/Fogarty International Center, NIH, Bethesda, Maryland 
 Abstract.  Initial responses to questionnaires used to assess participants’ understanding of informed consent for 
malaria vaccine trials conducted in the United States and Mali were tallied. Total scores were analyzed by age, sex, liter-
acy (if known), and location. Ninety-two percent (92%) of answers by United States participants and 85% of answers by 
Malian participants were correct. Questions more likely to be answered incorrectly in Mali related to risk, and to the type 
of vaccine. For adult participants, independent predictors of higher scores were younger age and female sex in the United 
States, and male sex in Mali. Scores in the United States were higher than in Mali ( P = 0.005). Despite this difference par-
ticipants at both sites were well informed overall. Although interpretation must be qualified because questionnaires were 
not intended as research tools and were not standardized among sites, these results do not support concerns about system-
atic low understanding among research participants in developing versus developed countries. 
 *Address correspondence to Joseph Millum, Clinical Center 
Department of Bioethics/Fogarty International Center, National 
Institutes of Health Building 10, 1C118 10 Center Drive, Bethesda, 
MD 20892. E-mail:  millumj@cc.nih.gov 
869COMPARISON OF INFORMED CONSENT IN US AND MALI
NIAID, and by either the Western IRB (JHU/CIR) or the 
Ethics Committee of the Faculty of Medicine, Pharmacy, and 
Dentistry of the University of Bamako, Mali. All trials were 
conducted under Good Clinical Practice and International 
Conference on Harmonization guidelines. 4 
 Questionnaires for all persons screened for participation 
were reviewed for this study. At JHU/CIR, age and sex were 
recorded as part of the baseline demographic information; all 
volunteers could sign their names and were considered to be lit-
erate. Written questionnaires were provided to volunteers and 
responses were reviewed with volunteers after answers were 
marked. In Mali, age and sex were available for the adults giv-
ing consent for their own participation, and the ability to sign 
one’s name was used as a surrogate for literacy. Consent docu-
ments were translated into French in Mali, but consent pro-
cedures, including administration of the questionnaires, were 
conducted orally in the local language, which does not have a 
written form. Malian volunteers who were unable to sign finger-
printed the consent form with a witness co-signing. For parents 
and guardians who gave consent for their child’s participation, 
age and sex of the consenting adult was not recorded and the 
only demographic information available was signature versus 
fingerprint. At both the Mali and United States sites consent 
procedures were conducted by clinical investigators. 
 SURVEY 
 A true/false questionnaire was administered by an investiga-
tor after the informed consent document had been reviewed. 
The questions are shown in  Table 1 . Questions that were 
answered incorrectly were used as teaching points, with the 
correct answer explained to the volunteer. All volunteers were 
expected to answer all questions correctly before additional 
screening procedures or enrollment. The questions focus on 
elements generally agreed to be necessary for valid consent, 
such as study procedures and design, possible risks, the absence 
of benefit, and participants’ right to withdraw at any time. 1, 18 
 The questionnaires for the two United States trials contained 
14 questions that were identical or very similar, and one ques-
tion that was different. Data for these trials were pooled for all 
but the question that differed, which was discarded. The ques-
tionnaires used for the trials in Mali were almost identical to 
each other, except that in the child study the question regard-
ing pregnancy was eliminated. Seven questions were judged 
to be the same or similar at the United States and Mali sites 
(indicated by asterisks in  Table 1 ). Responses to these seven 
questions were used to analyze effects of age, sex, literacy, and 
location (United States versus Mali), as described below. 
 DATA ANALYSIS 
 The proportions of correct responses to each question 
were summarized using descriptive statistics. A cumulative 
logistic regression was performed on each of the three data 
sets (United States Adults, Mali Adults, and Mali Parent/
Guardians) with overall score as the dependent variable. 
Independent variables included age group (18–25, 26–35, and 
over 35 years of age), sex, and literacy. The effects from the 
cumulative logistic regression were expressed as odds ratios 
(ORs). A similar analysis was used to compare scores between 
the United States and Mali adults using only the seven ques-
tions judged to be similar between the sites. (Data from the 
Mali Parent/Guardians was not used for this comparative 
analysis as only literacy was known for these subjects.) The 
 P values were by Wald test, except for the overall location 
effect, which was by likelihood ratio test. 19 The SAS version 
9.1 (SAS Institute, Cary, NC) was used for the analysis. 
 RESULTS 
 Participant demographics.  A total of 960 participants from 
the United States and Mali completed consent questionnaires. 
The response rate for both studies was 100%, because 
completing the questionnaire was a necessary part of the 
consent process. There were 171 adults in the United States 
trials (JHU/CIR participants) with a median age of 30 
(range 18–50). Fifty-six percent were male, 44% were female. 
There were 89 Malian adults with a median age of 27 (range 
18–50). Seventy-three percent (73%) of Malian adults were 
male and 27% female. Only 9% of Malian adults signed the 
consent form; the other 91% used a fingerprint. All literate 
Malian adults (able to sign one’s name) were male and < 25 
years of age. There were 700 Malian parents or guardians of 
whom 84% used a fingerprint on the form. The literacy rate 
for parents/guardians varied between sites with 3% literate in 
Donéguébougou and 17% literate in Bancoumana. 
 Understanding.  Initial responses to each question for the 
three trials are summarized in  Table 1 . In the trials conducted 
in the United States, 92% of initial answers for all questions 
were correct; Malian adults and parents/guardians answered 
correctly 85% of the time. On 5 of the 7 questions judged to be 
the same or similar among the studies (marked with an asterisk 
in  Table 1 ) the proportion of participants answering correctly 
was similar between the United States and Mali. Regarding 
the question about being injected with live malaria parasites, 
only 47% of Malian adults and 64% of Malian parents/
guardians recognized this as false. Similarly, 61% of Malian 
adults and 48% of Malian parents/guardians mistakenly said 
that the vaccine had been given to hundreds of people and 
was completely safe. However, there was a high frequency 
of errors in the final answers for this particular question in 
Mali. For the parents/guardians, 20% (143/700) of entries 
were either initially incorrect (true) and not corrected by the 
investigator, or were initially correct (false) but an incorrect 
answer was subsequently recorded as final. Errors were also 
discovered for some other questions in both this and the other 
Mali study, but with much lower frequency (6% or less). No 
errors in questionnaire administration were seen in the trials 
conducted in the United States. 
 Eighty percent of Malian adults and 90% of parents/guard-
ians answered a question about randomization correctly; 96% 
and 93%, respectively, understood that they could withdraw 
their consent, compared with 98% of United States partici-
pants. In the United States studies, 40% answered all ques-
tions correctly on the first attempt, while in the Mali studies 
22% of adults and 29% of parents/guardians did so. 
 Predictors of understanding.  Demographic variables (age, 
sex, literacy) were available for United States adults and for 
Malian adults consenting for their own participation. In the 
United States studies, younger age was associated with higher 
scores (OR for the two younger groups relative to the oldest 
group 2.1 and 2.5, respectively;  P = 0.02) and female sex was 
marginally associated with higher scores (OR female/male = 
1.7;  P = 0.06). In Malian adults, the effects for age and literacy 
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were not significant ( P = 0.45 and  P = 0.39, respectively), 
although the number of literate volunteers was very small, thus 
limiting power. The only significant independent predictor of 
higher scores in Malian adults was male sex (OR male/female 
= 3.2;  P = 0.02); as opposed to the United States adults, where 
female sex was associated with higher scores. For the Malian 
parents/guardians, literacy was significantly associated with 
higher scores (OR = 2.8;  P < 0.0001); no other variables were 
available. 
 In the analysis of the seven questions common to both sites, 
literacy was non-significant ( P = 0.70) and age was marginally 
significant (OR for younger groups 1.5 and 2.1;  P = 0.09). The 
location effect was significant, with higher scores in the United 
States compared with Mali adults ( P = 0.005). 
 DISCUSSION 
 The questionnaires used in these clinical trials were intended 
for teaching participants rather than for collecting data, and 
these data therefore have several limitations, as discussed later. 
However, the data presented here allow the first direct com-
parison of the quality of understanding of participants in simi-
lar clinical trials in developed and developing countries, and 
allow exploration of the predictors of understanding at sites in 
both the United States and Mali. Although there was a higher 
level of understanding in the United States volunteers com-
pared with those in Mali, the overall level of understanding of 
participants in Mali was almost as good as that of participants 
in the United States who had presumably far higher levels of 
education, with the exception of two questions. These data do 
not support concerns about a systematic lack of understanding 
among research participants in developing as compared with 
developed countries. 
 Overall, in this study 80% or more of initial answers were 
correct in all three groups. This compares favorably with previ-
ous studies of understanding in both developed and developing 
countries, although a lack of standardized instruments makes 
precise comparison with the other studies impossible. For 
example, another study of understanding among participants 
in a different malaria vaccine trial in Mali resulted in correct 
answers to multiple choice questions by between 7% and 73% 
of participants. 20 A study of parents of child participants in a 
South African tuberculosis vaccine trial whose authors judged 
its results “encouraging” showed correct recall between 37% 
and 85% of the time. 21 Likewise, a cross-sectional survey of 
participants in 73 different Phase 1, 2, and 3 oncology trials 
in the United States revealed widespread confusion about the 
purpose, procedures, and risks of trial participation. 22 
 United States participants had a much better understand-
ing on two questions—concerning experimental procedures 
and risks—and a small but significant improved understand-
ing overall. Results may have been biased by the high rate of 
Question (correct answer) % Correct
United States adult participants ( N = 171)
1 * . As part of this study, you will be injected with a live malaria parasite (false) 94
2.  This vaccine will protect you from getting malaria (false) 89
3 * . There is a chance you could have local reactions (pain, redness, swelling, itching) at the site of the injection (true) 99
4 * . Women enrolled in this study must not be pregnant or nursing (true) 96
5 * . If you change your mind about being in the study after you are vaccinated, you can withdraw your consent (true) 98
6 * . This vaccine has been given to hundreds of people already, so we know it is completely safe (false) 85
7.  You will receive an injection of the same vaccine once monthly for (3 or 2) months (true) 84
8 * . If you feel sick during the study, you should keep it to yourself (false) 99
9 * . If you join this study, you will need to be followed for a total of (8 or 6) months (true) 81
10. Before joining the study you will be tested for HIV, Hepatitis B, and Hepatitis C (true) 99
11. You will fill out a diary card for 6 days after each vaccination (true) 90
12. It is ok to enroll in other investigation agent studies while you are still in this study (false) 98
13. It is important for you to stay in the clinic for (60 or 30) minutes after each injection (true) 93
14. You cannot get malaria from this vaccine (true) 88
Mali adult participants ( N = 89)
1 * . As part of the study, you will be injected with a live malaria parasite (false) 47
2 * . There is a chance you could get sick from this vaccine (true) 88
3 * . Women enrolled in this study should not become pregnant up until 1 month after the last shot (true) 98
4 * . If you change your mind about being in the study after you are vaccinated, you can withdraw your consent (true) 96
5 * . This vaccine has been given to hundreds of people already, so we know it is completely safe (false) 61
6.  You will have your blood drawn as part of this study (true) 100
7.  You will get two vaccinations in this study (true) 92
8 * . If you feel sick during the study, you shouldn’t tell anyone (false) 89
9 * . If you join the study, you will need to be followed in our clinic for 7 months (true) 99
10. Everybody in this study will get the same kind of vaccine (false) 80
Mali parents/guardians of child participants ( N = 700)
1 * . As part of the study, your child will be injected with a live malaria parasite (false) 64
2 * . There is a chance your child could get sick from this vaccine (true) 83
3 * .  If you change your mind about your child being in the study after your child is vaccinated, you can withdraw your consent for your 
child (true)
93
4 * . This vaccine has been given to hundreds of people already, so we know it is completely safe (false) 48
5.  Your child will have blood drawn as part of this study (true) 99
6.  Your child will get two vaccinations in this study (true) 96
7 * . If your child feels sick during the study, you shouldn’t tell anyone (false) 94
8 * . If your child joins the study, your child will need to be followed in our clinic for 12 months (true) 99
9.  Everybody in this study will get the same kind of vaccine (false) 90
 Questions marked with an asterisk (*) were judged to be the same or similar among the studies. 
 Table 1 
 Frequency of correct answers by question 
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errors detected in questionnaire administration in Mali for one 
question regarding risk. However, this question (“This vaccine 
has been given to hundreds of people already, so we know it 
is completely safe”) was also one of the questions less likely 
to be answered correctly in the United States. This question 
may have been especially problematic, because it contains two 
concepts: “This vaccine has been given to hundreds of people 
already,” and “we know it is completely safe.” Risk was the 
concept least well understood in the previous study of under-
standing in Mali and was also poorly understood by oncology 
patients in the United States. 20, 22 
 More than 90% of participants at all sites correctly answered 
the question regarding withdrawal of consent. This contrasts 
with other studies indicating that participants in the devel-
oping world are more likely to feel pressured into enrolling 
into research, 12, 23 and often have a poor understanding of their 
right to withdraw. 10, 20, 24 
 Over 80% of Malian participants correctly answered the 
question about randomization (“Everybody in this study will 
get the same kind of vaccine,” correct answer false). Although 
the United States vaccine trials in this assessment of con-
sent were also randomized, this question was not included in 
the United States questionnaires. In previous studies in both 
developed and developing countries it is frequently the case 
that 50% or fewer participants understand that they will be 
randomized. 13, 25, 26 
 In the Mali child study, scores for parents/guardians were 
higher for those who were literate; however, no data were 
available for age and sex so whether this is a true effect of lit-
eracy or rather because of age or sex, which are confounded 
with literacy in Mali (younger males being more likely to be 
literate), is not known. Notably, though illiteracy is associated 
with lower understanding, the high scores for Malian partici-
pants, who were mostly illiterate, suggest that illiteracy need 
not be a barrier to valid consent. In both countries younger 
volunteers were more likely to achieve higher scores. This is 
consistent with previous research indicating that increased age 
may be a predictor of lower understanding. 27, 28 
 The study has several limitations. The questionnaires were 
intended for teaching participants, rather than for collecting 
data. Some of the differences observed may have resulted 
from different modes of conveying the information: potential 
participants in the United States received written question-
naires, whereas most participants in Mali consented orally. 
Results from one developed and one developing country 
may not generalize to other contexts. Moreover, the com-
parative analysis rests on just seven questions concerning 
understanding that were the same or very similar between 
the sites. A study specifically designed to compare under-
standing among trial participants at different sites, and one 
that covered all aspects of the requirements for informed 
consent, would be needed to draw more comprehensive con-
clusions. However, the opportunities to gather such data are 
rare, and this study is a unique “snapshot” of understand-
ing of consent in a set of clinical trials conducted in widely 
varying settings yet still using similar investigational prod-
ucts and similar protocols. Continued efforts to enhance 
understanding at both sites are ongoing, and questionnaires 
have been revised for greater clarity. Women in Mali, men 
in the United States, and older volunteers at both sites may 
particularly benefit from more intensive efforts to increase 
understanding. 
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